Fucana e Fucana radiomarcada (99mTc-Fucana) como um novo agente teranóstico de processos inflamatórios

• Autor(a) principal: Costa, Bianca
• Data de Publicação: 2022
• Outros Autores: [e-mail]
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da UERJ
• Texto Completo: http://www.bdtd.uerj.br/handle/1/18724
• topic: Fucoidan; Inflamation; Diagnosis; Therapy; Technetium-99m; Radiopharmaceutical; Fucana; Inflamação; Diagnóstico; Terapia; Tecnécio-99m; Radiofármaco; ENGENHARIAS::ENGENHARIA NUCLEAR::APLICACOES DE RADIOISOTOPOS

Inflammation is a vital defense mechanism, but failure in the resolution phase or its constant activation promotes disruption of homeostasis at multiple levels and contributes to the development and exacerbation of many diseases. The development of new products effective in the treatment and diagnosis of inflammatory processes will make an important contribution to the treatment of various pathologies with an inflammatory character. In this study, the applicability of Fucoidan as a therapeutic and imaging agent was investigated. For therapeutic purposes, this sulfated polysaccharide was tested in two inflammatory models: Arthritis (Zymosan) and Pneumonia (LPS). For use as an imaging agent, Fucoidan was labeled with 99mTc and its uptake in inflamed lungs (LPS) was measured and compared to uptake in non-inflamed lungs. The results showed that Fucoidan has a therapeutic anti-inflammatory effect, an effect that was evident in the lung model (LPS). The biodistribution assay showed that radiolabeled Fucoidan (99mTc-Fucoidan) has an important tropism for inflammatory foci with very relevant bioaccumulation, allowing us to consider its use as a nuclear imaging agent.